| Literature DB >> 18851739 |
María Eugenia Esandi1, Zulma Ortiz, Evelina Chapman, Marcelo García Dieguez, Raúl Mejía, Ricardo Bernztein.
Abstract
BACKGROUND: In the last decades, a sustained increment of Clinical Practice Guidelines (CPG) production in the world has been accompanied by a growing concern about their quality. Many studies related to quality assessment of guidelines produced in High Income Countries were published; however, evidence on this topic is scarce in Low and Middle Income Countries (LMIC). The objectives of this research were: a) to describe guideline production in Argentina at different levels of the health system (macro, meso and micro) from 1994 to 2004; and b) to assess their quality by using the AGREE instrument.Entities:
Year: 2008 PMID: 18851739 PMCID: PMC2572637 DOI: 10.1186/1748-5908-3-43
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Description of the searching strategy employed in Medline
| 1 | ("guideline" [Publication Type] OR "guidelines" [MeSH Terms] OR "guidelines" [Text Word]) |
| 2 | ("consensus" [MeSH Terms] OR consensus [Text Word]) |
| 3 | algoryth* |
| 4 | #1 OR #2 OR #3 |
| 5 | argentin* |
| 6 | #4 AND #5 |
Internet searching: institutions included at each level of Health System
| Organisms of the national, provincial and municipal State in charge of health policy formulation, execution and control. It includes: a) | |
| Websites of Health Technology Assessment agencies were also included at this level. | |
| Intermediate institutions of the public, private and social security sector that provide or manage health services. It includes: individual providers, organizations of providers and health assurance institutions. | |
| It is theoretically constituted by individual health professionals. In practice, scientific or professional associations were selected. Only national organizations were included. |
Figure 1Temporal evolution of the total number of CPG produced per year Ref: (†): Estimated by χ.
Amount of CPG produced by level and institutions of the Health System
| Macro | National Health Ministry | 13 |
| Provincial Public Health Department | 0 | |
| Local Public Health Department | 0 | |
| Health Technology Assessment Agencies (n = 2) | 0 | |
| Meso | Public and Private Hospitals | 15 |
| Hospitals Network | 0 | |
| Prepaid Enterprises | 0 | |
| Social Security Organizations | 23 | |
| Micro | Scientific Societies | 76 |
| More than one level | Macro/Meso/Micro | 3 |
| Macro/Micro | 14 | |
Figure 2Results of the analysis of the 101 Argentine guidelines on the six AGREE instrument domains.
Scores by item of the AGREE instrument
| Median value | Interquartile range | |
| 1. The overall objective(s) of the guideline is (are) specifically described | 1.5 | 1.5 |
| 2. The clinical question(s) covered by the guideline is (are) specifically described | 2 | 1 |
| 3. The patients to whom the guideline is meant to apply are specifically described | 2.5 | 1.5 |
| 4. The guideline development group includes individuals from all the relevant professional groups | 1.5 | 1 |
| 5. The patients' views and preferences have been sought | 1 | 0.5 |
| 6. The target users of the guideline are clearly defined | 1 | 1 |
| 7. The guideline has been piloted among end users | 1 | 0 |
| 8. The systematic methods were used to search for evidence | 1 | 0 |
| 9. The criteria for selecting the evidence are clearly described | 1 | 0 |
| 10. The methods used for formulating the recommendations are clearly described | 1.5 | 0.5 |
| 11. The health benefits, side effects and risks have been considered in formulating the recommendations | 2 | 1 |
| 12. There is an explicit link between the recommendations and the supporting evidence | 1 | 1 |
| 13. The guideline has been externally reviewed by experts prior to its publication | 1 | 0.5 |
| 14. A procedure for updating the guideline is provided | 1 | 0 |
| 15. The recommendations are specific and unambiguous | 2.5 | 1.5 |
| 16. The different options for management of the condition are clearly presented | 2.5 | 1.5 |
| 17. Key recommendations are easily identifiable | 2.5 | 1.5 |
| 18. The guideline is supported with tools for application | 1 | 0.5 |
| 19. The potential organizational barriers in applying the recommendations have been discussed | 1 | 0.5 |
| 20. The potential cost implications of applying the recommendations have been considered | 1 | 0 |
| 21. The guideline presents key review criteria for monitoring and/or audit purposes | 1 | 1 |
| 22. The guideline is editorially independent from the funding body | 1 | 0 |
| 23. Conflicts of interest of guideline development members have been recorded | 1 | 0 |
Figure 3Temporal evolution of the median standardized score for each AGREE instrument domain.
Comparison of CPG quality according to independent variables
| Period 1994–2000 (n = 22) | 39% [40%] | 15% [22%] | 6% [10%] | 42% [46%] | 6% [17%] | 0% [0%] |
| Year 2001 (n = 13) | 33% [47%] | 12% [29%] | 10% [15%] | 42% [46%] | 0% [19%] | 0% [0%] |
| Year 2002 (n = 19) | 33% [28%] | 8% [17%] | 10% [15%] | 50% [67%] | 6% [6%] | 0% [8%] |
| Year 2003 (n = 28) | 39% [29%] | 13% [13%] | 12% [11%] | 43% [40%] | 11% [19%] | 0% [0%] |
| Year 2004 (n = 19) | 28% [39%] | 13% [17%] | 8% [14%] | 33% [25%] | 6% [11%] | 0% [8%] |
| P value | ||||||
| Published (n = 39) | 39% [33%] | 13% [46%] | 10% [14%] | 42% [29%] | 6% [17%] | 0% [0%] |
| Not Published (n = 62) | 39% [33%] | 10% [13%] | 12% [14%] | 44% [38%] | 11% [17%] | 0% [0%] |
| P value | ||||||
| Macro (n = 12) | 42% [44%] | 11% [13%] | 61% [42%] | 11% [18%] | 0% [0%] | |
| Meso (n = 25) | 28% [31%] | 12% [12%] | 37% [37%] | 6% [11%] | 0% [0%] | |
| Micro (n = 49) | 39% [32%] | 7% [14%] | 41% [28%] | 6% [11%] | 0% [0%] | |
| More than one level (n = 15) | 39% [50%] | 12% [17%] | 41% [37%] | 6% [22%] | 0% [0%] | |
| P value | ||||||
| National CPG (n = 74) | 39% [33%] | 13% [13%] | 10% [15%] | 42% [34%] | 6% [18%] | 0% [0%] |
| Regional/Local CPG (n = 27) | 28% [25%] | 8 % [13%] | 12% [14%] | 38% [38%] | 6% [11% ] | 0% [0%] |
| P value | ||||||
| Dx/treatment management (n = 71) | 39% [28%] | 13% [13%] | 9% [14%] | 6% [17%] | 0% [0%] | |
| Prevention (n = 25) | 39% [50%] | 13% [19%] | 9% [12%] | 6% [17%] | 0% [0%] | |
| P value | ||||||
Reliability scores of the AGREE instrument
| Reliability measures | |||
| Single Rater ICC (95% CI) | Average of raters ICC (95% CI) | Cronbach alpha | |
| Scope | 0,33 (0,24–0,42) | 0,74 (0,65–0,81) | 0.75 |
| Participation | 0,09 (0,05–0,16) | 0,46 (0,28–0,61) | 0.55 |
| Rigour | 0,09 (0,05–0,14) | 0,58 (0,45–0,70) | 0.67 |
| Clarity | 0,26 (0,19–0,34) | 0,74 (0,65–0,81) | 0.82 |
| Applicability | 0,16 (0,09–0,24) | 0,53 (0,38–0,66) | 0.56 |
| Editorial Independence | 0,05 (-0,02–0,16) | 0,20 (-0,09–0,42) | 0.23 |